We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Genetic Markers Found for Breast Cancer Brain Metastasis

By LabMedica International staff writers
Posted on 06 Mar 2014
The development of brain metastases from breast cancer depends on several prognostic factors, including younger age, ethnicity, and hormone receptor negative status.

Other factors include the presence of Breast cancer 1, early onset (BRCA1) germ-line mutations, and the expression of the epidermal growth factor receptor 2 (Her2/neu) proto-oncogene, all of which contribute to an increased rate of brain metastasis. More...


Scientists at the Translational Genomics Research Institute (Phoenix, AZ, USA) obtained 35 retrospective fresh-frozen samples of breast brain metastases from other institutes and as well as non-neoplastic brain samples, and10 non-neoplastic breast tissue specimens. A series of 50 early-stage breast cancer, grade 1 and 2, specimens were also obtained.

Genomic DNA (gDNA) was isolated from fresh-frozen tissue using the DNeasy Blood and Tissue Kit (Qiagen; Valencia, CA, USA) and total ribonucleic acid (RNA), including small RNA, was isolated using the mirVana miRNA Isolation Kit (Ambion; Austin, TX, USA). RNA samples were evaluated for integrity using the Bioanalyzer RNA 6000 Nano LabChip Kit on a Bioanalyzer 2400 (Agilent Technologies; Santa Clara, CA, USA). The team performed deep genomic profiling, integrating gene copy number, gene expression, and DNA methylation datasets on the collection of the 35 breast-brain metastases samples.

Some of the common genetic alterations identified in the study were gains and losses in chromosome 8, as well as cell proliferation and cell-cycle progression, key mechanisms of cancer caused by genetic alterations, linked to the genes Aurora A kinase (AURKA), Aurora B kinase (AURKB) and Forkhead box protein M1 (FOXM1). The authors concluded that genomic and epigenomic profiling of breast brain metastasis provided insight into the somatic events underlying this disease, which have potential in forming the basis of future therapeutic strategies. Using the PAM50 breast cancer intrinsic classifier, Luminal B, Her2+/ER negative, and basal-like tumors were identified as the most commonly represented breast cancer subtypes in the brain metastasis cohort.

Nhan L. Tran, PhD, an Associate Professor and senior coauthor of the study said, “This groundbreaking study sets the stage for more exacting exploration, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousands of patients who urgently need our help.” The study was published on January 29, 2014, in the journal Public Library of Science One.

Related Links:

Translational Genomics Research Institute
Qiagen
Ambion



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Urine Analyzer
respons® UDS100
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.